See every side of every news story

Published 1 day ago • loading... • Updated 1 day ago

GLP-1 receptor agonists could hold promise for opioid use disorder treatment

Summary by Pharmaceutical-technology.com

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood sugar.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

1 Articles

All

Left

Center

Right

pharmaceutical-technology.com

GLP-1 receptor agonists could hold promise for opioid use disorder treatment

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood sugar.

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated1 day agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pharmaceutical-technology.com broke the news in 1 day ago on Friday, February 21, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics